Zag Bio is a Cambridge, Massachusetts-based startup that emerged from stealth with an $80 million Series A round led by T1D Fund and Polaris Partners 1 3 5 9 11 . The round included major investments from pharmaceutical companies AbbVie, Regeneron, and Sanofi 1 5 11 . Zag Bio's technology focuses on developing thymus-targeted therapies to modulate regulatory T cells (Tregs), which play a key role in immune tolerance 1 3 4 5 9 11 . Their approach is intended to restore central immune tolerance by delivering antigens specifically to the thymus, promoting the production of antigen-specific Tregs while reducing antigen-specific effector T cells 1 5 . CEO Jason Cole describes the company's strategy as intentionally moving in a new direction by targeting the 'natural mechanisms in the thymus,' differentiating Zag Bio from other players in the autoimmune field 1 . The startup plans to bring its lead candidate, aimed at treating Type 1 diabetes, into Phase 1 clinical ...
- Get link
- X
- Other Apps